Last reviewed · How we verify
Esperoct
At a glance
| Generic name | Esperoct |
|---|---|
| Also known as | Turoctocog alfa pegol (N8-GP) |
| Sponsor | Novo Nordisk A/S |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
- Hereditary factor VIII deficiency disease
Common side effects
- Factor VIII inhibition
- Rash
- Injection site reaction
- Drug hypersensitivity
- Redness
- Itching (pruritus)
Serious adverse events
- Neutralizing antibodies to Factor VIII (Factor VIII inhibitor)
Key clinical trials
- Pharmacokinetic Comparison of Efanesoctocog Alfa vs Other EHL-rFVIII Products in Participants With Severe Haemophilia A (PHASE1)
- Efficacy and Safety of Turoctocog Alfa Pegol (N8-GP) for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Chinese Patients With Haemophilia A (pathfinder10) (PHASE3)
- Safety and Efficacy of Turoctocog Alfa Pegol (N8-GP) in Previously Untreated Patients With Haemophilia A (PHASE3)
- A Study Following Males With Haemophilia A on Prophylaxis With Esperoct®
- Adverse Event Data Collection From the EUHASS Registry on Turoctocog Alfa Pegol
- Post-Marketing Surveillance (Use-results Surveillance) With Esperoct®
- An Observational Research Study of the Health of Joints in People With Haemophilia Taking the Medicine Esperoct
- A Research Study Looking at How a Factor VIII Medicine Called Turoctocog Alfa Pegol (N8-GP) Works in People With Haemophilia A (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Esperoct CI brief — competitive landscape report
- Esperoct updates RSS · CI watch RSS
- Novo Nordisk A/S portfolio CI